Biopharmaceutical company Ardelyx Inc. (ARDX) is pacing toward its third-quarter earnings release, with recent product momentum and clinical milestones positioning the company for continued operational expansion. Shares last traded at $5.10, up 1.19% at the close on October 27, 2025, and edged up to $5.12 in after-hours trading.Company OverviewArdelyx is focused on developing therapies for gastroi...
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.